Tag Archives: Reboxetine

Nonstimulant medications in the treatment of adults with ADHD

Here are some important points regarding nonstimulants in the treatment of adults with ADHD. Tricyclic antidepressants and bupropion are second-line therapies. Antidepressant dosing of the agents appears necessary for attention deficit hyperactivity disorder efficacy. Serotonergic medications do not appear effective in the treatment of core attention deficit hyperactivity disorder symptoms but may be useful for… Read More »

Treatment of Social Anxiety Disorder

Current recommended treatment options for social anxiety disorder include pharmacotherapy and cognitive behavioural therapy (CBT). Although several randomised controlled trials (RCTs) have failed to show efficacy for beta-adrenoceptor antagonists in generalised social anxiety disorder (SAD), it has been suggested that these agents may be useful in non-generalised social anxiety disorder (SAD), patients with performance anxiety… Read More »

Minor Depression: Duloxetine, Venlafaxine, and Milnacipran

Serotonin-Norepinephrine Reuptake Inhibitors Several antidepressants have dual action at both serotonergic and noradrenergic receptors. The most notable are the serotonin/norepinephrine reuptake inhibitors, particularly extended-release venlafaxine (Wyeth’s Effexor XR) and milnacipran (bioMerieux-Pierre Fabre’s Ixel/Dalcipran, Asahi Kasei/Janssen-Kyowa’s Toledomin; available only in France and Japan). The noradrenergic and specific serotonergic antidepressants (NaSSAs) mirtazapine (Organon’s Remeron/Remergil), nefazodone (Bristol-Myers Squibb’s… Read More »

Pharmacodynamic Effects of Antidepressants

Antidepressants are not only effective in the treatment of depression but are also used in a variety of other conditions, including panic disorder, obsessive-compulsive disorder, social phobia, anorexia and bulimia nervosa. Since the development of iproniazid in the 1950s, a new antidepressant group has been released almost every decade, with the result that there are… Read More »

Choosing an Antidepressant for Treating Mood Disorder in Children and Adolescents

There are an ever-increasing number of antidepressants for the clinician to choose from and making the right choice may seem a daunting task. Which drug is going to work Although about 60 per cent of children and adolescents will respond to first-line antidepressants, it would seem sensible to try and choose one which has the… Read More »

Antidepressants for Treating Mood Disorder in Children and Adolescents

As described in site, the antidepressants available to the clinician include MAOIs and RIMAs, TCAs, SSRIs, nefazadone, the SNRI venlafaxine, reboxetine and mirtazapine. Studies of the use of these drugs in children and adolescents with major depression are, however, very limited. This section describes the few trials that there have been, with emphasis being given… Read More »

Depression During Pregnancy

Prevalence During pregnancy, approximately 20% of women have some depressive symptomatology, and about 10% develop a major depressive episode (MDE). These rates are comparable to those in non-pregnant women. Risk factors include prior history of depression, younger maternal age, limited social support, living alone, greater number of children, ambivalence about pregnancy, negative life events and… Read More »

Pharmacotherapy for Depression

Pharmacological treatments have gained popularity during the last 50 years as a method of treatment intervention for depression as well as for many other psychological disorders. They have been proven effective in ameliorating the symptoms for a large percentage of depressed individuals and are now the most common form of treatment for depression. The constraints… Read More »

Practical issues in using antidepressants

Factors influencing antidepressant choice Selective serotonin reuptake inhibitors (SSRIs) and dual-action antidepressants are the predominant first choice treatments for major depressive disorder, although the evidence in favor of superior efficacy compared to classical antidepressants is limited. Their superior safety and tolerability profiles account for their widespread use, yet side-effects are not insubstantial and vary across… Read More »

Second and third generation antidepressants

Selective Serotonin Reuptake Inhibitors Serotonin and norepinephrine reuptake inhibitor (SNRI) and other antidepressants Venlafaxine, milnacipran and duloxetine all inhibit both 5HT and norepinephrine reuptake, albeit in different ratios. Venlafaxine more potently inhibits the 5HT transporter, milnacaprin has more norepinephrine inhibiting effects and duloxetine appears to provide a more balanced dual inhibition. Desvenlafaxine succinate (DVS), an… Read More »